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Arnone M. Teresaa,b,c,, Rotolo Antoninoa,b,c, Assennato Pasqualea,b,c,
Novo Giuseppinaa,b,c, Corrado Eglea,b,c and Novo Salvatorea,b,c
Aims Different researches showed a correlation between
aldosterone, atherosclerosis and ischemia in the last
decade. Evidence exist about relationship between high
levels of aldosterone and augmented risk of cardiovascular
diseases, like hypertension, cardiac failure, coronary artery
disease and stroke. The objective of this study was to
determine the prognostic role of aldosterone in patients
with myocardial infarction.
Methods Population of the study includes 96 consecutive
patients admitted in our Department for ST-elevated and
non-ST-elevated myocardial infarction from June 2009 to
March 2012. Plasmatic aldosterone levels were dosed at
admission in hospital in all patients. A 2 years prospective
follow-up was performed and fatal events and nonfatal
events like reinfarction, congestive heart failure and
arrhythmias were recorded.
Results Aldosterone levels at admission were associated
with incidence of congestive heart failure (PU0.02),
ventricular arrhythmias (PU0.01) and all complications
(PU0.003) after 1-month follow-up. Moreover, high
aldosterone levels gave important information at medium
term (24W6 months). Specifically, aldosterone was a
predictive variable of reinfarction (P<0.0001), congestive
heart failure (P<0.0001) and adverse events (PU0.0002).
The logistic regression analysis confirmed these results
and showed that aldosterone may be predictive of adverse
events at medium term follow-up [OR 1.1 (1.03–1.15); 95%
confidence interval, PU0.02].
Conclusion These data show a strong and significant
correlation between aldosterone plasmatic levels at
admission for myocardial infarction and fatal and nonfatal
adverse events. Aldosterone appears a main marker of
adverse clinical outcome according with literature. These
data suggest necessity to identify if antialdosteronic drugs
treatment, applied acutely in patients with aldosterone
elevation, can influence favorably prognosis of patients with
myocardial infarction.
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Introduction
The first study that clarified the role of aldosterone in
myocardial infarction has been conducted by Beygui
et al.1 who analyzed the relationship between plasma
aldosterone and outcome of patients with ST elevation
myocardial infarction (STEMI) and without left ventri-
cular dysfunction or heart failure.
The study enrolled 356 patients, undergoing Percuta-
neous Coronary Intervention (PCI) for STEMI,
who were divided in four quartiles and monitored for
6 months. Results of the study showed that higher levels
of aldosterone were associated with higher incidence of
ventricular fibrillation (P¼ 0.02), heart failure (P¼ 0.005)
and cardiovascular death (P¼ 0.03) during hospital stay.
Moreover, patients of the highest quartile had worse
outcome at 6 months than patients with lower levels
of aldosterone independently from age, heart failure
and successful reperfusion. Subsequently, the same
group conducted a new study to determine the effect
of spironolactone in patients with STEMI, showing
that antialdosteronic drugs provide a lower incidence
of arrhythmias and cardiac arrest.2
According to Beygui et al. data, Palmer et al.3 reported that
aldosterone levels correlate with long-term mortality of
patients with AMI. The study recruited 546 patients with
STEMI or non-STEMI and without postinfarction heart
failure. Over 80% of patients had non-STEMI and
follow-up was 5 years. These data, therefore, confirm
results of Beygui et al. extending conclusions to the larger
group of non-STEMI patients who were more than 80%
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of the total cohort. In addiction, levels of plasma
aldosterone were elevated beyond the normal range in
only a small percentage of patients suggesting that
higher concentration of plasma aldosterone, within the
normal range, may have an important impact on long-
term survival.
Finally, the LURIC study, that considered a large
cohort of normotensive and hypertensive patients with
and without coronary artery disease, heart failure and
acute coronary syndrome, demonstrated that higher
levels of plasma aldosterone, although within the
normal range, correlate with overall and cardiovascular
mortality.4
A recent meta-analysis, which considered 19 randomized
controlled trials and a total of 10 807 patients, confirmed
the negative effect of aldosterone in patients with chronic
heart failure and IMA, reporting a 20% reduction in all-
cause mortality in patients treated with mineralocorticoid
receptor antagonists.5
Primary objective of our study was to evaluate relation
between plasmatic aldosterone levels at hospital
admission and mortality (for cardiovascular disease or
for all causes) and complications incidence (reinfarction,
ventricular fibrillation, left ventricular insufficiency) at
short term (less than 30 days after hospitalization) and at
medium term (24 6 months) in patients admitted for
myocardial infarction in our Operative Unit of Cardiology
of University Hospital ‘Paolo Giaccone’ of Palermo.
In addiction our study wanted evaluate efficacy of
spironolactone on fatal and nonfatal adverse events
reduction.
Materials and methods
The study included patientsAQ3 of every sex that were
admitted for ST elevated and Non-ST-elevated myo-
cardial infarction from June 2009 to March 2012 in our
Operative Unit of Cardiology and that underwent to
coronarography. Diagnosis of STEMI was made, accord-
ing to the current guidelines, in those patients referred to
our division for a typical chest pain lasting more than
20 min and with a persistent ST-elevation reflecting an
acute and total occlusion of the artery responsible for the
myocardial infarction.6 A diagnosis of non-STEMI was
made, always according to the current guidelines, in
patients referred for typical chest pain but without a
persistent ST elevation, when a positive value of troponin
was found.7 Exclusion criteria of the study were:
potassium saver diuretics treatment before myocardial
infarction, severe renal failure (creatinine >2.5mg%),
potassium levels more than 5mmol/l, respiratory insuffi-
ciency, severe hepatic disease, malignant neoplasia or
terminal cachexia, active infective diseases, mental
disorders or linguistic barriers, that impeded adequate
comprehension and collaboration.
All patients underwent to accurate medical history, objec-
tive clinical examination, standard ECG, echocardio-
graphy, samples for specific myocardial enzymes, blood
glucose, total cholesterol, low density lipids (LDL), high
density lipids (HDL), triglycerides, creatinine, BUN AQ4,
serum electrolytes, AST levels, ALT levels, coagulation.
Left ventricular ejection fraction (LVEF), end-systolic
volume, end-diastolic volume were evaluate with trans-
thoracic echocardiography. Echocardiographic evaluation
will performed with echocardiography ‘Acuson Sequoia’.
Chamber dimension, LVEF and systolic function, valve
function and morphology, pattern Doppler and diastolic
function were assessed with conventional echocardio-
graphy AQ5. LVEF was measured by modified biplane
Simpson method.
Plasmatic aldosterone was dosed at admission in hospital
in all patients by a commercial radioimmunoassay
kit (ALDO-RIACT, Schering AG, Berlin, Germany).
Considered normal range was 8–172 pg/ml.
Data about coronary anatomy, stent or bypass presence
and about drugs that were administered during cardiac
catheterization (heparin, aspirin, clopidogrel, abciximab)
were recorded in every patient. TIMI flow grade was
evaluated in patients that underwent to angioplasty.
Observation period of our prospective study lasted
24 months and, for medium term follow-up, information
about fatal and nonfatal adverse events were recorded
contacting patients to conduct a clinical examination or, if
it was not possible, contacting them, their relatives or
their medical doctors with telephonic interviews.
Recorded data were about cardiovascular and noncardio-
vascular death and further hospitalizations for cardio-
vascular reasons (reinfarction, congestive heart failure
and arrhythmias).
Data management and statistical analysis
Statistical analysis was affected using Statview program
(Abacus Concepts Inc.). Mean and SD were calculated
for numeric variables and differences were obtained
between groups by Student’s t test. Prevalence of clinical
and laboratory variables and difference between groups
were calculated by x2 statistical test. Considered signifi-
cant statistic level was P< 0.05.
Results
Three hundred and fifty-six patients were admitted
in our intensive unit of cardiology with diagnosis of acute
coronary syndrome from June 2009 to March 2012.
Ninety-six patients with myocardial infarction that
underwent to coronarography were recruited, 70 with
ST-elevated myocardial infarction diagnosis and 26 with
non-ST-elevated myocardial infarction diagnosis. All
patients were informed at moment of enrollment about
protocol and did consent to study participation. Median
age of participants was 65 years, 57% was men and 57%
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had familiar history for myocardial infarction. Regarding
other principal cardiovascular risks, 69.7% presented
hypertension before myocardial infarction, diabetes
mellitus type 2 was present in 29.2%, dyslipidemia in
33.3%, obesity in 33.7% and smoke in 40.6%.
Basal characteristics of our population showed moderate-
high risk patients with myocardial infarction, 31% with
age at least 75 years, 23%with history of acute myocardial
infarction, 42.7% with anterior or anterior-septal or
anterior-lateral acute myocardial infarction. Median
levels of aldosterone in our population was 71.3 pg/ml.
Mean ejection fraction of left ventricle at transthoracic
echocardiography was 50%. In particular 40.5% of
patients showed a normal ejection fraction (EF) and only
18.2% showed systolic dysfunction of left ventricle,
defined to EF less than 40% presence. All patients
underwent to coronary and ventricular catheterization
that showed an involvement of one vessel in 51.6% of
cases, an involvement of two vessels in 24.2% and a
multivessel involvement in 24.2% of patients. Only in
2.5% of cases a full spontaneous reperfusion happened.
Ninety percent of patients were treated with primary PCI
and coronary stent application, with a successful reperfu-
sion in 95% of patients. Remaining 5% of patients needed
an aortic-coronary bypass. Patients that underwent to
aortic-coronary bypass were 10.4% in all.
Global population was divided in three groups in accord
with plasmatic aldosterone levels tertiles. Every tertile
was defined by aldosterone levels 19.0 or less (I), from
19.1 to 66.0 (II), at least 66.1 pg/ml (III).
Patients treated with antialdosteronic drugs and standard
therapy were 30 and they were distributed in plasmatic
aldosterone levels tertiles: specifically nine in I tertile,
10 in II tertile and 11 in III tertile. Comparison between
clinical characteristics of every tertile of patients is
reported in Table 1.
Comparing recorded data during echocardiographic
examination, there were not any statistically significant
differences between tertiles, considering ejection
fraction, end-systolic volume and end-diastolic volume.
At last, first and second tertiles were more frequently
associated, but not significantly, with a less severe
coronary disease, contrary to third tertile.
During hospital stay only two deaths occurred after
ventricular. These complications occurred during hospi-
tal stay: cardiogenic shock in 2.1%, congestive heart
failure in 11.46%, reinfarction in 3.1%, ventricular fibril-
lation in 4.2% and atrial fibrillation in 8.3% of patients.
Cardiogenic shock, ventricular fibrillation and death
occurred only in patients of the third tertile. Cardiac
heart failure kept a higher frequency in the higher tertile
(21.9%) than in the second tertile (12.5%); re-infarction
occurred in 6.25% of cases of third tertile and in 3.1% of
the second tertile, and minor arrhythmias (atrial fibrilla-
tion, supraventricular tachycardia and atrial tachycardia)
occurred more frequent in the third and in the second
tertile (9.4%, respectively) than in the first one (6.25%).
The rates of in-hospital events in different groups,
according to the baseline tertiles of plasma aldosterone
levels, showed an almost stepwise increase in rates of
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Table 1 Basal characteristicsAQ8 in agreement with plasmatic aldosterone levels tertiles
Variables Tertile 1 Tertile 2 Tertile 3 P
Age 6217 6714 6413 Nsa
Male sex (%) 56 41 75 0.02
Previous AMIb (%) 22 22 25 Ns
Hypertension (%) 62.5 87.5 59.4 0.02
Diabetes (%) 28 28 31 Ns
Smokers (%) 53 18.7 50 0008
Dyslipidemia (%) 28.1 40.6 31.5 Ns
BMI (kg/m2), meanSD 26.44.5 28.95.4 27.46.6 Ns
SBP (mmHg), meanSD 12920 14420 13726 Ns
DBP (mmHg), meanSD 7712 8113 8012 Ns
Ejection fraction (%), meanSD 508 5010 489 Ns
AMI location (%) Ns
Anterior wall 37.5 43.75 50
Inferior wall 53 34.4 34.4
Lateral wall 9.4 25 15.6
Angiographic characteristics,% Ns
1 vessel 25 40.6 28
2 vessels 34.4 9.3 28.1
Multivessel 15.6 31.2 25
Aldosterone (pg/ml), meanSD 11.85.0 35.512.4 16795 <0.0001
Troponine (ng/ml) meanSD 34.233 21.327 40.369 Ns
C Reactive protein (pg/ml), meanSD 2.12.9 22.5 2.63.5 Ns
Fibrinogen (mg/dl), meanSD 339122 38190 37889 Ns
Triglycerides (mg/dl), meanSD 136.873 108.840 14367 Ns
Total cholesterol (mg/dl), meanSD 176,338 173.739 18946 Ns
LDLc (mg/dl), meanSD 105.836 103.633 11743 Ns
HDLd (mg/dl), meanSD 41.413 52.120.7 43.814 Ns
a Ns, NOT significant. b AMI, acute myocardial infarction. c LDL, low density lipids. d HDL, high density lipids.
AQ1
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congestive heart failure (P¼ 0.02), VF/VT (P¼ 0.01) and
all complications (P¼ 0.003) (Fig. 1).
So, higher levels of aldosterone at admission in patients
with myocardial infarction were correlated with a worst
short-term outcome.
Analyzing the group of 21 patients with fatal and nonfatal
in-hospital events (re-infarction, congestive heart failure,
ventricular fibrillation and cardiogenic shock), data
showed that these patients presented a median aldo-
sterone level of 132.4 versus 54.23 pg/ml (P¼ 0.0002)
in patients without in-hospital complication or death.
Clinical baseline characteristics of patients are reported
in Table 2 in two groups: one with adverse events during
follow-up and one without events.
Events rate during medium term follow-up was 35.1%
(26 patients); the following events occurred during the
follow-up: four cardiovascular deaths, two cardiogenic
shock, 15 cardiac heart failure and eight re-infarctions.
Patients with adverse events did not show a higher
statistically significant prevalence of principal negative
prognostic factors like diabetes (23.1 versus 27.1%) or
anterior infarction (50 versus 46%).
Higher aldosterone levels were associated with adverse
events (re-infarction, congestive heart failure, ventricular
fibrillation, cardiogenic shock) (P¼ 0.0002) and patients
with these events showed a mean aldosterone level of
130.15 versus 60 pg/ml of patients without complications.
In addiction, analyzing percentage of affiliation to
plasmatic aldosterone tertiles in the group of patients
with events, 4.8% belongs to I tertile, 23.8% to II tertile
and 71.4% to III tertile.
Other predictive variables of adverse events at univariate
analysis were previous infarction (P¼ 0.02) and ejection
fraction (P¼ 0.0004).
Analyzing specific events and their relations with
aldosterone levels, higher levels of aldosterone were
associated with higher incidence of re-infarction
(210.25 148.1 versus 69.5 73.9; P< 0.0001) and con-
gestive heart failure (162.3 134 versus 64.9 70.2;
P< 0.0001) (Fig. 2).
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Table 2 Basal characteristics of patients in relation to presence of absence of adverse events during follow-up
Variables Events No events P
Age, meanSD 6815 6512 Nsa
Male gender (%) 65.4 65.12 Ns
Previous AMIb (%) 34.6 12.5 0.002
Hypertension (%) 76.9 64.6 Ns
Diabetes (%) 23.1 27.1 Ns
Smokers (%) 34.6 35.4 Ns
Dyslipidemia (%) 46.15 33.3 Ns
BMI (kg/m2), meanSD 258 285 Ns
SBP (mmHg), meanSD 13426 14023 Ns
DBP (mmHg), meanSD 7812 8113 Ns
Ejection fraction (%), meanSD 4510 538 0.0004
AMI location (%)
Anterior wall 50 46 Ns
Inferior wall 19.2 40 Ns
Lateral wall 19.2 6.25 Ns
Angiographic characteristics (%)
1 vessel 32 36.2 Ns
2 vessels 15.4 10.6 Ns
Multivessel 23.1 27.6 Ns
Aldosterone (pg/ml), meanSD (median) 130.15118 6068 0.001
Troponin, (ng/ml), mediaSD 26.835 41.559 Ns
C Reactive protein (pg/ml), meanSD 1.91.6 33.9 Ns
Fibrinogen (mg/dl), meanSD 389100 392100 Ns
Triglycerides (mg/dl), meanSD 12349 12456 Ns
Total cholesterol (mg/dl), meanSD 18146 17844 Ns
LDLc (mg/dl), meanSD 10940 11141 Ns
HDLd (mg/dl), meanSD 4614 4517 Ns
a Ns, Not significant. b AMI, Acute Myocardial Infarction. c LDL, Low Density Lipids. d HDL, High Density Lipids.
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Logistic regression analysis was applied to variables that
were significant at univariate analysis: previous infarction,
ejection fraction and aldosterone. Purpose of our study
was to evaluate which variables were predictive of
adverse events (Table 3); aldosterone and ejection frac-
tion were the only predictive independent variables of
adverse events [OR 1.1 (1.03–1.15), 95% confidence
interval (CIAQ6 ); P¼ 0.02 and OR 0.9 (0.85–0.98), 95% CI;
P¼ 0.009].
In addiction, considering that 30 patients (10 in every
tertile) were treated with spironolactone after hospital
stay, relationship between administration of antial-
dosteronic drugs and outcome was analyzed in our study.
Data of this analysis showed only a trend in reduction of
adverse events in patients treated with spironolactone
in comparison with patients that were not treated with
antialdosteronic drugs (eight events versus 21 events;
P¼ 0.08)
Discussion
The role of Aldosterone in cardiovascular pathophysio-
logy was suggested for the first time by presence of
mineralcorticoids receptors in vascular tissues, including
heart. After that moment, different research confirmed
the important pathophysiologic role of aldosterone in
cardiovascular system.8
Indeed, mineralcorticoid receptors activation have pro-
inflammatory, prothrombotic and profibrotic effects
that contribute to development and progression of
cardiovascular damaging effects that include: acute endo-
thelial dysfunction, reduced nitric oxide bio-availability,
augmented endothelial oxidative stress for increased
ROS generation, augmented cardiovascular tone,9
reduced coronary flow, inhibition of tissues catechol-
amine receptors, thrombogenesis, fast necrosis of vascular
and myocardial smooth muscular cells, deposition of
collagen in blood vessels, hypertrophy and myocardial
fibrosis.
Different studies suggest that infusion of aldosterone
can acutely induces a reduced coronary perfusion in
healthy volunteers.10 The principal mechanism seems
the augmented oxygen free radicals synthesis and
the endothelial dysfunction due to NADPH-oxidase.11
Prothrombotic action of aldosterone involves different
adverse effects on endothelial cells, like reduction of NO
release, stimulation of plasminogen activator inhibitor 1
synthesis and increase of ROS and NADPH oxidase
enzyme expression.
Several potential mechanisms could contribute to
elevation of plasmatic aldosterone levels after an acute
myocardial infarction. Stimulation of renin-angiotensin-
aldosterone after a myocardial infarction and high
angiotensin II levels, are probably the most important
factors that contribute to increase aldosterone secretion.
Also activation of hypothalamus–pituitary–adrenal gland
axis can contribute, considering that this axis is early
stimulate after an acute myocardial infarction and
that adrenocorticotropic hormone is a powerful short-
term secretagogue of aldosterone.
Central pathophysiologic role of aldosterone in heart
failure was confirmed and underlined in import-
ant clinical trials, like RALES12 and EPHESUS.13
These studies showed that spironolactone and eplere-
none gives beneficial effects in patients with heart failure
and reduced ventricular ejection fraction, expanding
indication of antialdosterone drugs in heart failure.
Beygui et al.1 analyzed correlation between plasmatic
aldosterone and outcomes in STEMI. They showed
that aldosterone plasmatic levels were associated with
higher incidence of fatal and nonfatal events in patients
with diagnosis of ST-elevated myocardial infarction that
underwent to primary PCI.
Purpose of our study was to evaluate correlation between
plasmatic aldosterone levels in patients with myocardial
infarction and short-term outcome and its prognostic
role at medium term (2 years).
Results of our work showed that elevated aldosterone
plasmatic levels were associated with adverse outcome,
finding higher percentage of adverse events in the third
aldosterone tertile as proof of direct proportionality
between neuroormonal activation grade and prognosis.
Differences between tertiles were statistically significant
for cardiac insufficiency (P¼ 0.02), VF/VT (P¼ 0.01) and
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Aldosterone levels in relation to incidence of reinfarction, heart failure
and total fatal and nonfatal events.
Table 3 Univariate andmultivariate analysis for predictive variables
of fatal and non fatal events during mean term follow up
Variables
Univarite
analysis
Multivariate analysis
OR (95% CI); P
Aldosterone (pg/ml) P¼0001 1,1 (1,03–1,15); P¼0.02
EFa (%) P¼00004 0,9 (0,85–0,98); P¼0009
Previous infarction P¼0,02 2,5 (0,67–9,8); P¼0.17
a EF, ejection fraction.
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total complications (P¼ 0.003) during hospital stay, and
for cardiac heart failure (P< 0.0001), reinfarction
(P< 0.0001) and total complication (P¼ 0.001) during
2 years follow-up. Other predictive variables of worse
outcome were ejection fraction (P¼ 0.0004) and previous
infarction (P¼ 0.002) at univariate analysis. Extending
literature data, our study also demonstrated that elevated
aldosterone plasmatic levels are an independent pre-
dictive variable of adverse events like showed from
multivariate analysis: aldosterone and ejection fraction
maintained their statistical significance with a P value of
0.02 and 0.009, respectively (Table 3).
In conclusion, these data show a strong and significant
correlation between aldosterone plasmatic levels at
admission for myocardial infarction and fatal and nonfatal
adverse events: higher versus lower aldosterone plasmatic
levels are associated withmedium and short-term adverse
clinical events.
So aldosterone appears a main marker of adverse
clinical outcome. These results extend Beygui et al.1 data
on prognostic significance of plasmatic aldosterone levels
at short and medium term.
The study of Palmer et al.3, that was performed on a larger
cohort of patients, with a mean follow-up of 5 years,
confirmed results of Beygui et al. study in patients
with STEMI and in patients with non-STEMI that
constituted 80% of the considered cohort.
Considering our results and data of literature about
prognostic role of plasmatic aldosterone and considering
that subgroup of patients treated with spironolactone
showed a trend of lower rate of adverse events,
there is necessity to identify if antialdosteronic drugs
treatment, applied acutely in patients with aldosterone
elevation, can influence favorably prognosis in a general
setting of patients with myocardial infarction, expanding
knowledge of historic RALES12 and EPHESUS13 trials.
In addition, whereas only 10.4% of the study population
had levels of plasma aldosterone above normal values
(8–172 pg/ml), it is possible to assume that beneficial
effects on morbidity and mortality post-MI could be
using antialdosteronic drugs in patients with myocardial
infarction whose plasma levels of the hormone are not
above the normal range. Data obtained from Pitt’s et al.
study are in agreement with this hypothesis and showed
that aldosterone reduce left ventricular hypertrophy in
hypertensive patients with low levels of aldosterone
concentration.
Limitations of our study are: first, the small number
of patients studied, due to important exclusion criteria
like renal failure and active infective diseases; second,
the effects of plasma aldosterone levels on long-term
(5 years) clinical outcomes were not considered; third
the serum levels of aldosterone were measured at
admission; changes over time or their potential change
due to various medications were not examined.
Finally, a limitation of this and all similar studies is the
fact that circulating concentrations of aldosterone before
the ischemic event remain unknown.
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